Global Spine Biologics Market Size is Expected to Reach $2.4 Billion by 2020

Date: 2015-11-28

Spine Biologics Market, By Product (Bone Grafts, Bone Grafts Substitutes, Platelet-rich Plasma, Bone Marrow Aspirate Therapy), By Surgery Type (Anterior Cervical Discectomy and Fusion (ACDF), Posterior Lumbar Interbody Fusion (PLIF), Transforaminal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), Lateral Lumbar Interbody Fusion (LLIF)), by Geography – Global Forecasts to 2020

Spinal biologics are devices that are used extensively for bone fusion surgery, spinal cord injury, and degenerative disk disease. The treatment may include the use of allografts, autografts, mesenchymal stem cells, demineralized bone matrix, bone morphogenetic protein, and ceramics. These materials assist the body’s natural healing processes and are used to heal spine diseased or degenerated discs. The effects is perceived through increased cellular activity, growth, and differentiation. For example, in case of materials such as pedicle rods and screws used in spine fusion cases to provide spinal stability and fusion healing. However, since metals are inert in nature, they do not stimulate or activate cellular growth or alter cellular functions such as natural healing. Biologic materials are increasingly being preferred by surgeons performing spinal fusion surgeries as their use facilitates the fusion process due to their stimulant effect on spine fusion. The global spine biologics market constituted 33.5% of the global spinal implants and spinal devices market in 2014.

Spine biologics find application in spine surgery as lieu allografts as well as a support for bones in and around the spinal region. They can also be used cure the spinal injuries or trauma or degenerated discs. Currently, bone morphogenetic proteins (BMP’s) are biologic materials that are predominantly used in spinal surgery. Bone graft substitutes claim for around 85% share of the total spine biologics market.

The global spine biologics market size is expected to reach $2.4 billion by 2020, at a CAGR of 4.4% during the forecast period of 2015 to 2020. Growing aging population and rise in the application of minimally invasive surgeries are the major factors influencing the growth of this market.

The global spine biologics market report studies the major regions, namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW).

In 2014, North America estimated accounted for the largest share of the global spine biologics market. As growth of healthcare industry is affected by the healthcare expenditure, increased investments in life sciences are expected to fuel the growth of the global spine biologics market in this region. The European spine biologics market is the second-largest. APAC is estimated to be the fastest growing market for spine biologics during the forecast period.

The report includes company profiles of major players, recent activities in the market, new product launches, mergers & acquisitions, collaborations and partnerships, and SWOT analysis. Some of the companies profiled in this report are Medtronic Inc. (U.S.), DePuy Synthes Companies (U.S.), Zimmer Holding Inc. (U.S.), Nuvasive Inc. (U.S.), Stryker Corporation (U.S.), Orthofix International N.V. (U.S.), K2M Inc. (U.S.), Exactech Inc. (U.S.), and Wright Medical Technology Inc. (U.S.), among others. 

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample